FDA slaps a partial hold on Avidity's mAb-siRNA therapy, pausing enrollment in muscle weakness disease study

Avidity Biosciences will have to wait to enroll new patients in a Phase I/II study of its therapy for myotonic dystrophy type 1, or DM1 …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA slaps a par­tial hold on Avid­i­ty's mAb-siR­NA ther­a­py, paus­ing en­roll­ment in mus­cle weak­ness dis­ease study